This cytokine plays a pivotal role in mediating both articular cartilage damage and systemic bone loss.2 To counteract these destructive processes, TNF-α neutralizing therapies, such as Adalimumab and Infliximab, have been developed in clinical practice to treat RA-associated inflammation and joint erosion.3 This evidence concerns the gene TNF and rheumatoid arthritis.